NICE bars obesity pill from routine NHS use
Cost regulators for NHS treatments in England and Wales are standing by their position that Orexigen’s weight loss pill Mysimba can not be recommended as a cost-effective treatment option.
Read More
Tag: naltrexone
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
